ARROWHEAD PHARMACEUTICALS, INC. Net Income Loss

• ARROWHEAD PHARMACEUTICALS, INC. showed an increase of +99.7% in Net Income Loss from 2024 to 2025.
• This data is from ARROWHEAD PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on November 25, 2025.
• XBRL data for this metric is available from 2005 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 16 years of available data (2005 to 2025), ARROWHEAD PHARMACEUTICALS, INC.'s Net Income Loss has grown by 75.8%.
• Historical annual values: Fiscal year 2025: -$1.63 million | Fiscal year 2024: -$599.49 million | Fiscal year 2023: -$205.28 million | Fiscal year 2022: -$176.06 million | Fiscal year 2021: -$140.85 million | Fiscal year 2020: -$84.55 million | Fiscal year 2019: $67.98 million | Fiscal year 2018: -$54.45 million | Fiscal year 2017: -$34.38 million | Fiscal year 2016: -$81.72 million | Fiscal year 2015: -$91.94 million | Fiscal year 2014: -$58.63 million | Fiscal year 2013: -$31.14 million | Fiscal year 2012: -$21.13 million | Fiscal year 2011: -$3.13 million | Fiscal year 2005: -$6.73 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026